Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC
Status:
Unknown status
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The optimum regimen of maintenance treatment after first-line chemotherapy in patients with
metastatic colorectal cancer (mCRC) is unknown. This study was designed to determine the
efficacy and safety of maintenance treatment with capecitabine metronomic chemotherapy versus
conventional chemotherapy.